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Compared to other cyclooxygenase-2 inhibitors, celecoxib is associated with a lower
cardiovascular risk, though the mechanism remains unclear. Angiotensin II is an
important mediator of oxidative stress in the pathophysiology of vascular disease.
Cyclooxygenase-2 may modify the effects of angiotensin II though this has never been
studied in humans. The purpose of the study was to test the effects of selective
cyclooxygenase-2 inhibition on plasma measures of oxidative stress, the vasoconstrictor
endothelin-1, and nitric oxide metabolites, both at baseline and in respose to
Angiotensin II challenge in healthy humans. Measures of 8-hydroxydeoxyguanosine,
advanced oxidation protein products, nitrotyrosine, endothelin-1, and nitric oxide
metabolites were assessed from plasma samples drawn at baseline and in response
to graded angiotensin II infusion (3 ng/kg/min × 30min, 6 ng/kg/min × 30min)
before and after 14 days of cyclooxygenase-2 inhibition in 14 healthy subjects (eight
male, six female) in high salt balance, a state of maximal renin angiotensin system
suppression. Angiotensin II infusion significantly increased plasma oxidative stress
compared to baseline (8-hydroxydeoxyguanosine; +17%; advanced oxidation protein
products; +16%), nitrotyrosine (+76%). Furthermore, levels of endothelin-1 levels
were significantly increased (+115%) and nitric oxide metabolites were significantly
decreased (−20%). Cycloxygenase-2 inhibition significantly limited the increase in 8-
hydroxydeoxyguanosine, nitrotyrosine and the decrease in nitric oxide metabolites
induced by angiotensin II infusion, though no changes in advanced oxidation protein
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products and endothelin-1 concentrations were observed. Cyclooxygenase-2 inhibition
with celecoxib partially limited the angiotensin II-mediated increases in markers of
oxidative stress in humans, offering a potential physiological pathway for the improved
cardiovascular risk profile of this drug.
Keywords: blood pressure, celecoxib, cycloxygenase-2 inhibition, endothelin-1, humans, oxidative stress, nitric
oxide, renin-angiotensin system
INTRODUCTION
Compared to other cyclooxygenase-2 inhibitors, celecoxib is
associated with a lower cardiovascular risk (Solomon et al.,
2004; Hirayama et al., 2014; Nissen et al., 2016; Gunter et al.,
2017). Though the mechanism is unclear, animal studies suggest
that COX-2-inhibition plays a role in attenuating the effects
of Angiotensin II (AngII; Wu et al., 2005; Martínez-Revelles
et al., 2013) the effector molecule of the renin angiotensin
system (RAS), which plays a central role in the pathophysiology
of hypertension, an important risk factor for cardiovascular
disease (Touyz and Schiffrin, 2004; Mehta and Griendling, 2007).
The actions of AngII result in not only vasoconstriction but
also generation of reactive oxygen species (ROS; Mehta and
Griendling, 2007) stimulation of endothelin-1 (ET-1; Sasser et al.,
2002; Montanari et al., 2003) and depletion of nitric oxide (NO)
vascular bioavailability (Thomas et al., 2008) all of which have
been shown to promote atherosclerosis and increase vascular risk
(Touyz and Schiffrin, 2004), though in some circumstances, ROS
activation may be beneficial (Le Moal et al., 2017). Interestingly,
ET-1 synthesis and NO metabolism inhibition, both of which
induce vasoconstriction, have been shown to be ROS-mediated
(Sedeek et al., 2003; Thomas et al., 2008). It is therefore
possible that increased ROS production acts as a mechanism for
AngII to increase the vasoconstrictor/vasodilator ratio. Previous
human studies have shown a role for endothelin-1 through
measurement of hemodynamics after endothelin-A blockade
(Montanari et al., 2003) but we are not aware of any studies
that have simultaneously examined changes in oxidative stress,
endothelin-1 levels and nitric oxide metabolites in response
to an AngII challenge. Moreover, animal studies suggest that
cyclooxygenase-2 plays a role in attenuating these effects, mainly
via the reduction of the NADPH oxidase-dependent superoxide
anion generation (Martínez-Revelles et al., 2013; Wu et al.,
2005), suggesting that inhibition of this enzyme could blunt the
unfavorable oxidative stress effects of AngII, though this has
never been studied in humans.
Thus, the purpose of this study was two-fold: to determine
to effects of selective cyclooxygenase-2 inhibition on plasma
measures of oxidative stress, the vasoconstrictor endothelin-1
Abbreviations: 3-N, nitrotyrosine; 8-OHdG, 8-hydroxy-2’-deoxyguanosine; AngI,
Angiotensin I; AngII, Angiotensin II; AOPP, advanced oxidation protein products;
BP, blood pressure; COX-2, cyclooxygenase-2; EDTA, ethylenediaminetetraacetic
acid; ELISA, enzyme-linked immunosorbent assay; ET-1, endothelin-1; FRAP,
ferric reducing antioxidant power; NADPH, nicotinamide adenine dinucleotide
phosphate; NO, nitric oxide; NOx, end-products of nitric oxide metabolism; O.−2 ,
superoxide anion; ONOO−, peroxynitite; PRA, plasma renin activity; RAS, renin
angiotensin system; RIA, radioimmunoassay; ROS, reactive oxygen species.
and nitric oxide metabolites, both at baseline and in response to
Angiotensin II challenge in healthy humans. We hypothesized
that selective COX-2 inhibition would reduce markers of
oxidative and nitrosative stress, both at baseline and in response
to angiotensin II challenge.
MATERIALS AND METHODS
Ethics Approval
The study protocol was approved by the Conjoint Health
Research Ethics Board at the University of Calgary and
conformed to the standards set by the latest revision of the
Declaration of Helsinki. All subjects gave written informed
consent.
Subjects
Healthy, non-smoking, normotensive, non-diabetic, non-
pregnant adult subjects ingesting no medications from the
community were recruited to participate in the study. Subjects
completed an initial medical history, physical examination,
electrocardiogram, and laboratory screening. No subject was
ingesting any medication; specifically, no women were ingesting
the oral contraceptive as exogenous estrogen is known to affect
RAS (Ahmed et al., 2004) and ROS activity (Finco et al., 2011).
Protocol
Subjects consumed >200 mmol sodium/day for 3 days before
the study. Sodium and creatinine excretion were measured from
a 24 h urine collection or estimated from the second morning
void (Kawasaki et al., 1993). Given that variations in menstrual
cycle are associated with alterations in RAS (Chidambaram et al.,
2002) and ROS (Cornelli et al., 2013), all female subjects were
studied 14 days after the start of last menstrual period. Subjects
were studied in the supine position after an 8 h fast. At 08:00 h,
an intravenous catheter was placed in each arm (for infusion and
blood sampling). Blood pressure (BP) was recorded every 15min
by an automatic recording device (Dinamap; Critikon, Tampa,
FL). After a 90min equilibration period to establish baseline
hemodynamic measurements, a graded infusion of AngII at
3 ng/kg/min × 30min (30min), followed by 6 ng/kg/min ×
30min (60min) was administered, followed by a 30min recovery
period (90min) at which point the study ended. Plasma levels of
oxidative stress (i.e., 8-hydroxy-2′-deoxyguanosine [8-OHdG]),
advanced oxidation protein products [AOPP], total antioxidant
status (ferric reducing antioxidant power, FRAP), nitrative stress
(nitrotyrosine [3-N]) ET-1, and end-products of nitric oxide
metabolism (NOx) as well as circulating components of the RAS
(plasma renin activity, aldosterone), were collected at baseline
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and every 30min until the end of the study (30, 60, and
90min). Blood was collected in 7 ml ethylenediaminetetraacetic
acid (EDTA) tubes. The plasma and serum were obtained by
centrifugation of the samples at 1,000 g for 10min at 4◦C
immediately and 20min respectively after blood collection.
Plasma and serum were separated into aliquots and frozen at
−80◦C until assays could be performed. Subjects then ingested
the selective cyclooxygenase-2 inhibitor, celecoxib, at the clinical
dose of 200mg daily × 14 days, after which time they repeated
the AngII challenge study day. Compliance with the medication
was ensured by pill counting and regular telephone followup by
the study nurse. Study subjects were also asked to return pill
containers and any unused tablets.
Biochemical Analyses
Concentrations of plasma 8-OHdG were determined using an
enzyme-linked immunosorbent assay (ELISA) kit from Cell
BioLabs (Cell Biolabs, Inc., San Diego, CA), with limits of
detection 1–200 µg.l−1. Since DNA is known to be very sensitive
to ROS (Loft et al., 2008a), 8-OHdG, an end-product of DNA
oxidation, is one of the most reliable markers for oxidative stress
(Loft et al., 2008b) and was selected as the primary marker of
oxidative stress in this study. Concentrations of plasma AOPP
were determined using the semi-automated method described
by Witko-Sarsat et al. (1996) and concentrations were expressed
as micromoles per liter of chloramine-T equivalents. AOPP
is one of the most reliable markers for oxidative stress in
many inflammation processes (Witko-Sarsat et al., 1996; Pialoux
et al., 2009b). Concentrations of plasma nitrotyrosine, an end-
product of protein nitrosilation, were measured using an ELISA
kit from Cell BioLabs (Cell Biolabs, Inc., San Diego, CA)
with limits of detection 1–8000 nmol.l−1. Since tyrosine is
sensitive to nitrosilation by peroxynitite (ONOO−), the amount
of nitrotyrosine reflects the activity of ONOO−. Peroxynitite is
formed by the reaction of the superoxide anion (O.−2 ) with NO.
Plasma ferric reducing antioxidant power (FRAP) was assessed
according to the manual Benzie and Strain (Benzie and Strain,
1996) method and were measured by spectrophotometry at 37◦C.
FRAP concentration was calculated using an aqueous solution
of known Fe2+ concentration (FeSO4, 7H2O2) as standard
at a wavelength of 593 nm. FRAP is a global indicator of
antioxidant power. It has been reported that FRAP is negatively
correlated with oxidative stress after hypoxic exposure (Pialoux
et al., 2009a), highlighting the potential sensitivity of FRAP
to oxidative stress. Concentrations of plasma endothlin-1 were
measured using an ELISA kit (Cell Biolabs Inc., San Diego, CA).
The end-products of nitric oxide (NOx), nitrites, and nitrates,
were measured using a commercially available colorimetric
kit (Cayman Chemical Company, Ann Arbor, MI, USA). A
radioimmunoassay (RIA) was utilized for plasmas renin activity
(PRA; DiaSorin Clinical Assays, Stillwater, MN, USA). In brief,
Angiotensin I (AngI), the primary product of PRA was generated
at 37◦C from endogenous renin and renin substrate at pH 6.0.
The integrity of the generated AngI was maintained by inhibition
of proteolytic activity using EDTA and phenylmethylsufonyl
fluoride in the generation system. The accumulated AngI reflects
PRA under these controlled conditions. The AngI generated
TABLE 1 | Baseline and anthropometric characteristic of the subjects.
Males (n = 8) Females (n = 6)
Age (years) 32.3 ± 7.9 37.5 ± 15.4
Weight (kg) 84.4 ± 17.4 62.4 ± 8.6
Height (cm) 180.3 ± 11.3 162.7 ± 4.9
BMI (kg/m2) 25.6 ± 3.7 24.0 ± 3.7
Fat mass (%) 19.7 ± 4.7 29.1 ± 7.1
Glycaemia (mmol/L) 4.90 ± 0.35 5.00 ± 0.44
HbA1c (%) 5.22 ± 0.20 5.48 ± 0.20
Cholesterol (mmol/L) 4.12 ± 0.71 4.32 ± 0.65
Triglycerides (mmol/L) 1.22 ± 0.56 0.77 ± 0.41
24 h Na excretion (mmol/day) 405 ± 102 355 ± 73
24 h Cr excretion (mg/day) 2305 ± 334 1260 ± 160
was determined by RIA using competitive binding principles,
where the antibody was immobilized onto the lower inner
wall of coated tubes. Aldosterone was also measured using an
RIA assay. AngII plasma levels were measured by standard
laboratory immunoassay techniques (Quest Diagnostics; San
Juan Capistrano, CA, USA). Glycated hemoglobin was measured
using a colorimetric method (Integra 800 CTS, Roche, USA).
Plasma triglycerides were measured by enzymatic colorimetric
assay (Cobas 6,000, Roche, USA). Cholesterol was measured by
enzymatic colorimetric assay (Cobas 8,000, Roche, USA).
Statistical Analyses
Data are reported as mean ± standard deviations (SD) unless
otherwise indicated. The primary analysis of this exploratory
study tested the change in measures of oxidative stress, ET-1,
and NO at baseline and in response to a graded AngII challenge,
before and after COX-2 inhibition using a two-way repeated
measure ANOVA followed by Sidak post-hoc test. Statistical
analyses were performed using Stata (version 10.0; Stata, College
Station, TX) with two-tailed significance levels of 0.05.
RESULTS
Baseline Characteristics
Characteristics of the 14 study subjects are presented in Table 1.
Subjects were normotensive, non-obese, non-diabetic, and in
high-salt balance, a state of maximal RAS suppression, as
indicated by urine sodium excretion.
Responses to AngII Challenge Pre-COX-2
Inhibition
AngII increased all measures of oxidative stress (Table 2; 8-
OHdG: +17%, p = 0.02 at 90min (Figure 1); AOPP: +15 and
+16%, p = 0.01 at 30 and 60min), protein nitration (+76%, p
= 0.004 at 60min), FRAP: −13 and −14%, p = 0.04 at 60 and
90min). Similarly, AngII challenge resulted in an increase in ET-
1 (+93 and +115%, p < 0.001 at 60min and 90min; Figure 2)
and a decrease in NOx (−20%, p= 0.02 at 60 and 90min).
As anticipated, all subjects demonstrated significant changes
in all indices of blood pressure and circulating RAS components
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TABLE 2 | Measures of plasma oxidative stress, endothelin-1, products of nitric oxide metabolism, aldosterone and plasma renin activity at baseline and
in response to Angiotensin II infusion, pre- and post-cyclooxygenase-2 inhibition.
Pre-COX-2 inhibition Post-COX-2 inhibition
Baseline 30min 60min 90min Baseline 30min 60min 90min
AOPP (µmol.L−1 ) 83.2 ± 18.0 95.5 ± 22.6* 96.3 ± 21.8* 89.2 ± 22.8 69.5 ± 17.9 103.3 ± 24.6* 94.3 ± 23.4* 97.1 ± 22.5*
3-N (nmol.L−1) 23.5 ± 9.6 24.8 ± 10.1 41.4 ± 10.2* 24.0 ± 11.0 23.0 ± 9.6 27.7 ± 11.0 29.0 ± 13.1† 29.4 ± 17.8
FRAP (mmol.L−1 ) 1116 ± 107 1082 ± 151 975 ± 55* 957 ± 142* 996 ± 169 1104 ± 203 904 ± 94 877 ± 67
ET-1 (nmol.L−1) 1.04 ± 0.45 1.17 ± 0.36 2.01 ± 0.64* 2.24 ± 0.54* 0.92 ± 0.40 1.64 ± 1.28 2.32 ± 2.26* 2.31 ± 1.41*
NOx (µmol.L−1 ) 31.0 ± 5.7 27.4 ± 3.2 24.9 ± 3.0* 24.9 ± 4.1* 27.2 ± 7.1 26.1 ± 5.7 28.1 ± 5.5 25.8 ± 7.1
PRA (ng.mL−1.h−1) 0.26 ± 0.14 0.14 ± 0.09* 0.10 ± 0.07* 0.10 ± 0.07* 0.19 ± 0.15 0.13 ± 0.11* 0.11 ± 0.10* 0.12 ± 0.11*
Aldosterone (pmol.L−1 ) 175 ± 88 225 ± 134 357 ± 184* 282 ± 123* 125 ± 68† 190 ± 118 291 ± 158* 240 ± 129*
Values are presented as means ± SD. AOPP, advanced oxidation protein products; 3-N, nitrotyrosine; FRAP, ferric reducing antioxidant power; ET-1, Endothelin-1; NOx, end-products
of nitric oxide metabolism; PRA: Plasma renin activity. *p < 0.05 vs. corresponding baseline;
†
p < 0.05 vs. pre-COX-2 inhibition at same time point.
FIGURE 1 | Plasma oxidative stress (8-OHdG) at baseline and in
response to Angiotensin II infusion, pre- and post COX-2 inhibition. *p
< 0.05 compared to corresponding baseline value.
†
p < 0.05 vs.
corresponding timepoint pre-COX-2 inhibition.
in response to AngII challenge compared with baseline values
(Tables 2, 3).
Measures of Oxidative Stress, ET-1, and
NOx in Responses Post-COX-2 Inhibition
The changes in measures of oxidative stress, ET-1, and NOx
after COX-2 inhibition are outlined in Table 2 and Figures 1,
2. COX-2 inhibition abolished the increase in both 8-OHdG
and nitrotyrosine and the decrease in FRAP and NOx observed
in response to AngII challenge pre-COX-inhibition, though
no differences in the AOPP and ET-1 responses to AngII
infusion were observed. No difference was observed in the
hemodynamic and plasma renin activity responses to COX-2
inhibition (Tables 2, 3). However, COX-2 inhibition significantly
decreased baseline aldosterone levels (p = 0.03) and blunted the
aldosterone increase in response to AngII (p = 0.01; all p-values
vs. pre-COX-2 inhibition at same time point).
DISCUSSION
To our knowledge, this is the first study to examine the effects
of COX-2 inhibition on AngII-mediated increases of oxidative
stress, in addition to ET-1, a potent vasoconstrictor, and NO
metabolites, a proposed biological marker of vasodilatation
capacities and endothelial function (Heiss et al., 2006) in healthy
humans. Our key findings were as follows: (1) AngII induced
an increase in markers of oxidative stress; (2) AngII upregulated
ET-1; (3) AngII decreased measures of NO metabolites; and
(4) inhibition of COX-2 limited the AngII-mediated increase
in markers of oxidative stress. Our results expand on previous
animal studies (Wu et al., 2005; Martínez-Revelles et al., 2013),
and suggest that in addition to vasoconstriction, acute exposure
to AngII results in an unfavorable oxidative stress profile with
an increased vasoconstrictor agent (endothelin-1) to vasodilator
ratio offering a potential pathophysiological mechanism for the
endothelial dysfunction observed in high cardiovascular risk
populations. In this context, celecoxib appears to favorably
modulate the increase in oxidative stress in the setting of acute
AngII exposure.
Responses to AngII Challenge
Previous studies have suggested a role for AngII in the generation
of ROS (Sifi et al., 2017) More specifically, AngII modulates
vasoconstriction by acting through the AngII type 1 receptors
located in vascular smooth muscle (Mehta and Griendling,
2007) and growing evidence suggests that such detrimental
effects of AngII type 1 receptor activation are mediated
by oxidative stress through the activation of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase (Mehta and
Griendling, 2007; Li et al., 2016). The increase in blood pressure
resulting from AngII infusion may also in turn augments
ROS production via an increased shear stress. AngII induces a
transient increase in vascular smooth muscle cell COX-2 mRNA
accumulation and COX-2-derived prostanoid may contribute to
the pathophysiological conditions associated with elevated levels
of Ang II in the vasculature (Young et al., 2000).
Because endothelin-1 is known to be a potent vasoconstrictor
and mitogen it likely plays a role in the development of
hypertension (Channick et al., 2001; Remuzzi et al., 2002; Lin
et al., 2015). In our study, endothelin-1 was clearly upregulated
by AngII infusion. This result is consistent with other studies
showing that AngII stimulates the production and release
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FIGURE 2 | Plasma endothelin-1 at baseline and in response to Angiotensin II infusion, pre- and post-COX-2 inhibition. *p < 0.05 compared to
corresponding baseline value.
TABLE 3 | Measures hemodynamic parameters at baseline and in response to Angiotensin II infusion, pre- and post-cyclooxygenase-2 inhibition.
Pre-COX-2 inhibition Post-COX-2 inhibition
Baseline 30min 60min 90min Baseline 30min 60min 90min
SBP (mmHg) 117 ± 15 129 ± 18* 131 ± 15* 118 ± 14 115 ± 12 127 ± 12* 130 ± 13* 114 ± 11
DBP (mmHg) 70 ± 9 81 ± 9* 80 ± 11* 70 ± 8 68 ± 8 80 ± 10* 81 ± 11* 68 ± 10
MAP (mmHg) 86 ± 10 97 ± 11* 97 ± 12* 86 ± 9 84 ± 9 96 ± 10* 98 ± 11* 84 ± 9
Values are presented as means ± SD. SBP, systolic blood pressure; DBP, diastolic blood pressure. MAP, mean arterial pressure; PRA, Plasma renin activity. *p < 0.05 vs. corresponding
baseline.
of endothelin-1 (Pollock, 2005). Although controversial, some
authors suggest that hypertensive effects of AngII could be
mediated in part by endothelin-1 (Rossi et al., 1999). The
hypothesis that AngII stimulates the production and release of
endothelin-1 is supported by in vitro (Moreau et al., 1997; Hong
et al., 2004) and human (Jilma et al., 1997) studies. In rats,
endothelin-1 augmented the pressor response to angiotensin II
infusion (Yoshida et al., 1992). Interestingly, recent in vivo rat
data suggest that endothelin-1-induced vasoconstriction may be
dependent on the production of ROS (Thomas et al., 2008). It
is therefore possible that increased production of ROS could
be a mechanism for AngII to induce endothelin-1 synthesis
as occurs in the vascular dysfunction observed in the setting
of chronic kidney disease (Wang et al., 2015). Conversely, the
bioavailability of the potent vasodilator NO has been proposed to
be highly dependent on redox status. Under pathophysiological
conditions, an increase in ROS through activation of AngII has
been shown to decrease NO bioavailability (Sedeek et al., 2003).
More specifically, ROS inactivates NO synthesized by endothelial
nitric oxide synthase (eNOS) and can induce an uncoupling of
eNOS (Sedeek et al., 2003).
Responses to COX-2 Inhibition
This study is the first to report in humans that the COX-
2 inhibitor celocoxib attenuates AngII-induced oxidative stress
and decrease in NO metabolites. It has been previously shown
that selective COX-2 inhibition by celecoxib reduces oxidized
LDL in patients with coronary artery disease (Chenevard et al.,
2003). It has been demonstrated that COX-2 plays a role in
attenuating the AngII pro-oxidant effects via the reduction of
the NADPH oxidase-dependent superoxide anion generation
(Wu et al., 2005). Similar results were observed using a genetic
approach: COX-2 knockout mice demonstrate blunted Ang II-
induced oxidative stress and increase in blood pressure (Wu
et al., 2011). Taken together, these data suggest that celecoxib
has antioxidant properties and may lead to the preservation
of NO bioavailability and reduction of 3-NT as a stimulant of
peroxynitrite activity under AngII challenge (Senbel et al., 2014).
Nevertheless, in our study, the lack of change in measures of
oxidative stress at baseline highlight that the potential COX-2
inhibition associated-antioxidant properties appear to manifest
only in the setting of an acute AngII challenge. In support of
this, it has been demonstrated that angiotensin type 1 receptor
(AT1R) blockers inhibit oxidative stress activity in the heart in
the setting of hypertension (Bayorh et al., 2003; Dohi et al., 2003)
independently of their effect on blood pressure.
Although celecoxib globally decreased aldosterone, restored
NOx and potentially NO metabolism in response to AngII
infusion, no changes in blood pressure either at rest or in
response to AngII infusion were observed, son. These data in
humans confirm previous studies demonstrating that chronic
celecoxib treatment did not modify blood pressure in 2
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kidney-1 clip hypertension model rats (Richter et al., 2004).
The efficiency of selective COX-2 inhibition on systolic blood
pressure may be related to the model of hypertension-induced
(deoxycorticosterone acetate-salt model vs. our AngII infusion
model; Okumura et al., 2002).
In rats with induced cardiac hypertrophy, treatment with
celecoxib for 2–4 weeks suppressed pressure overload induced
cardiac hypertrophy via decreasing apoptosis, inflammation, and
oxidative stress (Zhang et al., 2016). In contrast and highlighting
a potential difference between the effects of selective COX-2
inhibitors, rats who underwent chronic treatment with rofecoxib
decreased oxidative stress through the reduction of the NADPH
oxidase-dependent superoxide anion generation (Wu et al.,
2005). Interestingly, this study reported that rofecoxib also
blunted the hypertensive response to 12 days of AngII treatment.
The differences between the reported effect of COX-2 inhibition
on blood pressure in this study and our results may reflect both
medication and interspecies differences as well as distinctions
between acute vs. chronic AngII exposure. Indeed, in healthy
rats, the superoxide dismutase mimetic tempol did not have any
effect on the pressor or renal hemodynamic response to acute
AngII infusion although it is able to reduce increases in mitogen
activated protein kinase activation and decreases in glomerular
filtration rate (López et al., 2003; Zhang et al., 2004). Finally,
Baber et al. (2005) showed that systemic pressor responses to
AngII infusion were not modified by COX-1 or COX-2 inhibitors
whereas it was attenuated by losartan an AT1R antagonist.
Despite the beneficial effects of NO and aldosterone responses
to AngII associated with exposure to celecoxib, no differences in
the endothelin-1 response to AngII challenge were observed. This
lack of effect in endothelin-1 may also explain the fact lack of
change in the blood pressure response to AngII were observed
with the ingestion of celecoxib despite the observed decreases
in the NOx and aldosterone responses to AngII. Although
endothelin-1 has been shown to play a role in modulating
COX-2 and COX-2-derived prostaglandin E2 cellular expression
(Spinella et al., 2004), it has not been shown to have a modulating
effect of COX-2 on endothelin-1, consistent with our plasma
endothelin 1 results.
The lack of change in the endothelin-1 response to AngII in
the present study may represent the difference between acute
and chronic exposures to AngII as the role of endothelin-1 in
inducing the increase in superoxide was not observed during the
first transient (measured after 10min in this study) superoxide
release induced by activation of the RAS (Laplante et al., 2005).
This latter result could explain the divergent effect of celecoxib
on oxidative stress and endothelin-1.
Strengths and Limitations
Healthy subjects were studied in the present investigation,
and as such, the results may not be generalizable to patient
populations. However, by including only healthy subjects, we
were able to eliminate potential confounding factors such
as diabetes, hypercholesterolemia, atherosclerosis, and obesity,
which may have affected our primary outcome. In addition,
although our findings are in keeping with animal studies using
an acute AngII challenge (Wu et al., 2005; Martínez-Revelles
et al., 2013), the shorter duration of AngII exposure may not
mimic a chronically activated RAS and our results should be
interpreted in this context. All the biomarkers of oxidative
stress measured in this study have been shown to be associated
with severity of cardiovascular disease (Ho et al., 2013). For
example, the JUPITER trial supported the clinical utility of
assessing inflammatory status in guiding intervention to limit
cardiovascular events (Ridker et al., 2008). We assumed the
change in circulating biomarkers in response to angiotensin
II was reflective of vascular wall activity for the purposes of
this study due to the necessary ethical limitations of human
investigation. Interestingly, despite this potential limitation, our
assays were sufficiently sensitive to detect the effect of Ang
II infusion and celecoxib treatment as demonstrated by the
significant difference between the conditions. The increase in
blood pressure in response to Ang II may in turn augment
ROS production via increased shear stress (Lo et al., 2013;
Ding et al., 2015). However, since the Ang II infusion identical
before and after celecoxib ingestion, the effects of COX-2 in
inhibition on the oxidative stress response to Ang II infusion
would not have been impacted. While sex-based differences in
the vascular response to AngII challenge have been previously
reported (Miller et al., 1999), this study was not powered to detect
sex differences in outcomes. However, we established a priori
that an individual subject’s response to each intervention would
be compared to his or her own baseline using a paired analysis,
thus taking into account the sex of the subject. Furthermore, no
differences were observed between the female and male response
to cyclooxygenase-2 inhibition or angiotensin II infusion in this
exploratory study. Finally, menstrual cycle variation and/or oral
contraceptive use may affect ROS generation (Finco et al., 2011;
Cornelli et al., 2013), but female subjects were studied at the mid-
point of the menstrual cycle and women using exogenous sex
hormones were excluded. Of the selective COX-2 inhibitors, only
celecoxib is approved for sale in Canada; as such, we were not able
to compare the effects of celecoxib to that of other selective COX-
2 inhibitors. Our results demonstrate an association between
celecoxib and blunting of the oxidative stress generated by
angiotensin II in healthy humans independent of sex, though
whether these findings apply to other selective COX-2 inhibitors
is unknown.
CONCLUSION
In summary, we have demonstrated that COX-2 inhibition with
celecoxib limited the increase in markers of oxidative stress and
the decrease in NO metabolites in response to AngII. Large,
prospective studies are warranted to determine how the results
of this study translate into clinical outcomes.
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